1. Fatal hyperparathyroid crisis;Keeling, C.A.; Abrahamson, M.J.; Hanloe, D.G.J.;Postgrad Med J,1987
2. Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and mechanism of action for glucocorticoid therapy;Mundy, G.R.; Rick, M.E.; Turcotte, R.; Kowalski, M.A.;Am J Med,1978
3. Prostaglandins as mediators of hypercalcaemia associated with certain types of cancer;Seyberth, H.W.; Segre, G.V.; Morgan, J.L.; Sweetman, B.J.; Potts, J.T.; Oates, J.A.;N Engi J Med,1975
4. Intravenous etidronate in the management of malignant hypercalcaemia;Ryzen, E.; Martodam, R.R.; Troxell, M.;Arch !nt Med,1985
5. Inhibition of osteolytic bone lesions by (3-amino-l-hydroxypropylidene)-l, 1-biphosphonate (APD);Van Breukelen, F.J.M.; Bijvoet, O.L.M.; van Oosterom, A.T.;Lancet,1979